PR Newswire Clinical TrialsOriginal article
RELIEF CARDIOVASCULAR REPORTS POSITIVE FIRST-IN-HUMAN DATA FOR DEVICE-BASED DECONGESTION THERAPY IN HEART FAILURE PATIENTS
Phase 1positiveDevice-based decongestion therapyPositive
AI Analysis
Summary
Relief Cardiovascular reported positive first-in-human data for its device-based decongestion therapy designed to reduce heart failure congestion by modulating venous pressure and enhancing renal flow. The RELIEF-FIH trial met primary and functional endpoints, confirming device safety and accurate hemodynamic sensing.
Clinical Trial Data
Phase
First-in-human
Primary Endpoint
Met
Outcome Details
RELIEF-FIH met primary and functional endpoints, confirming device safety, enhanced renal flow, and accurate hemodynamic sensing
Importance:7/10
Sentiment:
0.85
deviceheart failuredecongestionhemodynamicsfirst-in-humanpositive data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on March 3, 2026 5:00 PM